Trial Profile
Phase 2/3, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study To Evaluate the Efficacy and Safety of Certolizumab Pegol in Japanese Subjects With Moderate to Severe Chronic Psoriasis
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 02 Jun 2022
Price :
$35
*
At a glance
- Drugs Certolizumab pegol (Primary)
- Indications Erythrodermic psoriasis; Plaque psoriasis; Psoriatic arthritis; Pustular psoriasis
- Focus Therapeutic Use
- Sponsors UCB Biopharma
- 27 May 2022 Results of exploratory analysis of the efficacy and safety of certolizumab pegol in Japanese patients with generalized pustular psoriasis and erythrodermic psoriasis , published in the Dermatology and Therapy
- 28 Jan 2020 Results presented in a UCB media release.
- 28 Jan 2020 According to a UCB media release, the Japanese health authorities has approved CIMZIA (certolizumab pegol) to treat plaque psoriasis, psoriatic arthritis, pustular psoriasis and psoriatic erythroderma for which existing treatment methods are not sufficiently effective, based on the data from this study.